関連する実験動画

Updated: Sep 10, 2025

Continuous IV Infusion is the Choice Treatment Route for Arginine-vasopressin Receptor Blocker Conivaptan in Mice to Study Stroke-evoked Brain Edema

Continuous IV Infusion is the Choice Treatment Route for Arginine-vasopressin Receptor Blocker Conivaptan in Mice to Study Stroke-evoked Brain Edema

Published on: September 1, 2016

腎臓置換治療を長期にわたって受けている重症患者のレビティラセタム投与量

Sirichai Chusiri¹, Jirapat Vamananda², Dhakrit Rungkitwattanakul³

¹Department of Pharmacy Practice, Faculty of Pharmaceutical Sciences, Chulalongkorn University, 254 Phayathai Road, Pathumwan, Bangkok 10330, Thailand.

Journal of critical care

|August 24, 2025

まとめ

慢性腎臓置換療法 (PIRRT) を長期にわたって受けている重症患者の場合,標準レベチラセタムの投与量は不十分である可能性があります. 最適な投与量は,PIRRTの種類,頻度,および有効な発作制御のためのタイミングに依存します.

科学分野:

薬物動力学と薬物動力学
クリティカルケア医療
腎臓科

背景:

レベチラセタムは通常,発作の予防と治療に使用されます.
長期間の間歇性腎置換療法 (PIRRT) は薬のクリアランスに重大な影響を与える可能性があります.
PIRRTを受ける重症患者に対するレベチラセタムの限られた用量ガイドラインがあります.

研究の目的:

PIRRTを投与された重症成人におけるレベチラセタム療法の目標達成率 (PTA) を評価する.
治療薬の曝露を達成するために最適なレベチラセタム用量戦略を決定する.

主な方法:

1次排泄の1区画の薬理学モデルが開発されました.
モンテカルロシミュレーション (MCS) を用いて,様々なレベチラセタム療法を評価した.
シミュレーションでは,異なるPIRRT方式 (血液濾過,血液透析),排出量,持続時間,および薬物投与のタイミングが組み込まれました.

主要な成果:

一般的なレベチラセタム投与法は,シミュレートされたPIRRTシナリオで適切なPTAを達成できなかった.
最適な治療法は,PIRRTの方法と頻度によって異なる.
隔日ヘモフィルタレーションでは,500 mg q12hまたは1000 mg q24hが最適であり,血液透析では750 mg q12hまたは1250 mg q24hが好ましい.
PTAの目標を一貫して達成するために,毎日のPIRRTは750mg q12hが必要でした.

結論:

標準的なレベチラセタムの投与量は,PIRRTを受けている患者には不十分である可能性が高い.
PIRRTの特異性を考慮して,個別化された用量戦略が必要である.
これらのシミュレートされた用量推薦の臨床検証は必要である.

キーワード:

レベチラセタムモンテカルロシミュレーション薬理学長期間の間歇性腎臓置換療法

さらに関連する動画

A Large Animal Model for Acute Kidney Injury by Temporary Bilateral Renal Artery Occlusion

A Large Animal Model for Acute Kidney Injury by Temporary Bilateral Renal Artery Occlusion

Published on: February 2, 2021

Intravascular Delivery of Biologics to the Rat Kidney

Intravascular Delivery of Biologics to the Rat Kidney

Published on: September 1, 2016

関連する概念動画

Renal Failure: Dose Adjustments

Renal Failure: Dose Adjustments

In patients with renal impairment, drugs undergo significant changes in their pharmacokinetics, which require dosage adjustments to ensure safe and effective therapy.
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...

Continuous Renal Replacement Therapy

Continuous Renal Replacement Therapy

Continuous Renal Replacement Therapy, also known as CRRT, is a procedural treatment for acute kidney injury (AKI) that gradually removes uremic toxins and fluids while maintaining acid-base balance and stabilizing electrolytes. It is particularly useful for hemodynamically unstable patients. Unlike intermittent hemodialysis, which is faster, CRRT provides a gentler approach over 24 hours, closely mimicking the function of natural kidneys. However, CRRT is not ideal for patients with...

Acute Kidney Injury V: Interprofessional Care

Acute Kidney Injury V: Interprofessional Care

Acute Kidney Injury (AKI) requires a collaborative healthcare approach to restore renal function and prevent complications. Essential management strategies involve monitoring fluid and electrolyte balance, adjusting medications, initiating dialysis when necessary, and providing nutritional support.Fluid and Electrolyte ManagementFluid Monitoring: Regularly monitoring body weight, central venous pressure, and urine output helps detect fluid imbalances early. Patient intake and output are...

Acute Kidney Injury VI: Nursing Management

Acute Kidney Injury VI: Nursing Management

Acute Kidney Injury (AKI) results in an inability to maintain fluid, electrolyte, and acid-base balance. Effective nursing management is critical in improving patient outcomes and includes comprehensive patient assessment and targeted interventions.Comprehensive Patient AssessmentA detailed history collection is essential, focusing on any recent infections, nephrotoxic medication use, or chronic conditions such as hypertension and diabetes that may contribute to AKI. During the physical...

Acute Kidney Injury IV: Diagnostic Studies and Prevention

Acute Kidney Injury IV: Diagnostic Studies and Prevention

Accurate diagnosis and effective prevention are critical in managing Acute Kidney Injury (AKI), which is linked to high mortality rates ranging from 10% to 80%. Timely recognition of at-risk patients and careful monitoring can significantly reduce the likelihood of kidney damage.Diagnostic Assessments:The diagnostic process starts with a comprehensive medical history to identify prerenal, intrarenal, and postrenal causes.Prerenal causes, such as dehydration, hypotension, or blood loss, should...

Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein

Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein

Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...